SBRT plus osimertinib for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding precise, high-dose radiation (SBRT) to the targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has shrunk but not disappeared on osimertinib alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a specific type of advanced lung cancer (EGFR-mutant NSCLC) that is still present after at least 12 weeks on osimertinib.
- You have 5 or fewer remaining tumor spots in up to 2 organs that can be safely treated with focused radiation.
- You have stable enough health to undergo radiation (ECOG performance status 0-2).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Hear when a new EGF-R Positive Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.